Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Decoding KRAS dynamics: Exploring the impact of mutations and inhibitor binding.

Archives of biochemistry and biophysics - 1 Feb 2025

Pandey Divya, Roy Kuldeep K

Abstract excerpt

KRAS (Kirsten rat sarcoma viral oncogene homologue), the most common mutated protein in human cancers, is the leading cause of morbidity and mortality. Before Sotorasib (AMG-510) was approved for non-small cell lung cancer treatment in 2020, the oncogenic KRAS mutations were believed to be non-druggable. High-resolution X-ray crystal structures of GDP-bound KRAS mutants with and without inhibitor are resolved and...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Binding Sites
Share to Guanosine Diphosphate
Share to Molecular Dynamics Simulation

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Piperazines

Share to Protein Conformation

Share to Proto-Oncogene Proteins p21(ras)

Share to Pyridines

Share to Pyrimidines

Source

Identifiers

PMID: 39710177
DOI: 10.1016/j.abb.2024.110279

Genes

KRAS

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Decoding KRAS dynamics: Exploring the impact of mutations and inhibitor binding.PMID 39710177Read ↗

Structural insights into small-molecule KRAS inhibitors for targeting KRAS mutant cancers.Semantic proximity Read ↗

Analysis of KRAS-Ligand Interaction Modes and Flexibilities Reveals the Binding Characteristics.Semantic proximity Read ↗

Insight of the molecular mechanism of inhibitors located at different allosteric sites regulating the activity of wild type and mutant KRAS (G12).Semantic proximity Read ↗

Annual review of KRAS inhibitors in 2022.Semantic proximity Read ↗

Inside the cracked kernel: establishing the molecular basis of AMG510 and MRTX849 in destabilising KRASG12C mutant switch I and II in cancer treatment.Semantic proximity Read ↗

Exploring the GDP binding to KRas WT, G12C, G12D, G12R, and G12V and bound with MRTX1133 using steered molecular dynamics.Semantic proximity Read ↗

In Silico Study of the Acquired Resistance Caused by the Secondary Mutations of KRAS G12C Protein Using Long Time Molecular Dynamics Simulation and Markov State Model Analysis.Semantic proximity Read ↗

In silico comparative analysis of KRAS mutations at codons 12 and 13: Structural modifications of P-Loop, switch I&II regions preventing GTP hydrolysis.Semantic proximity Read ↗

Identification of KRAS mutants (G12C, G12D, and G12V) inhibitors.Semantic proximity Read ↗

Pharmacophoric analogs of sotorasib-entrapped KRAS G12C in its inactive GDP-bound conformation: covalent docking and molecular dynamics investigations.Semantic proximity Read ↗

The path to the clinic: a comprehensive review on direct KRASG12C inhibitorsSemantic proximity Read ↗

Structure-based inhibitor design of mutant RAS proteins-a paradigm shift.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.